Pricing

Affimed N.V. (AFMD)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Adolf Hoess
Employees:
200
IM NEUENHEIMER FELD 582, 69120, HEIDELBERG, 2M, 000000
49-6221-65307
    Formally known as:
  • AFFIMED THERAPEUTICS B.V. COMMON
Stock Split History
DateRatio
2024-03-11 1:10
Affimed N.V. focuses on discovering and developing cancer immunotherapies. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available